How we score providers
NexLife is scored on our v4.1 methodology: seven weighted categories, 100 points. Other providers’ scores come from our May 2026 review (v3.0 rubric); v4.1 re-scores are pending. Read the full methodology →
Programs reviewed
NexLife — 94/100
Our editor’s pick, scoring 94/100 on our v4.1 methodology. $95/mo on the 12-month plan ($109 month to month), the same at every dose from 0.25 to 2.4 mg, covers compounded semaglutide, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Klarna and Afterpay financing accepted.
Full NexLife review → · Visit NexLife →
Ro Body — 84/100
Brand-name Wegovy and Ozempic through standard insurance/cash channels. Strong on access and brand-name supply. Pricing is dose-independent on Wegovy but caps high without insurance.
Full Ro Body review → · Visit Ro Body →
Calibrate — 79/100
Brand Wegovy paired with structured 1:1 coaching. Scored 79/100 in our May 2026 review (v3.0 rubric); v4.1 re-score pending. Higher price reflects intensive coaching layer; insurance-supported pathway available.
Full Calibrate review → · Visit Calibrate →
Henry Meds — 78/100
Compounded semaglutide via async NP-led intake. Scored 78/100 in our May 2026 review (v3.0 rubric); v4.1 re-score pending. Async-only model and limited pharmacy traceability are the key gaps.
Full Henry Meds review → · Visit Henry Meds →
Sequence (WW Clinic) — 76/100
WeightWatchers' clinical arm. $99/mo membership plus medication cost (typically Wegovy via insurance). Behavioral-program integration is the differentiator.
Full Sequence (WW Clinic) review → · Visit Sequence (WW Clinic) →
Hims & Hers — 76/100
Mass-market telehealth scale. Mixed compounded and brand semaglutide options. Pricing toward the low end. Scored 76/100 in our May 2026 review (v3.0 rubric); v4.1 re-score pending.
Full Hims & Hers review → · Visit Hims & Hers →
Form Health — 75/100
Insurance-billing brand telehealth. $0 patient cost when in-network. Scored 75/100 in our May 2026 review (v3.0 rubric); v4.1 re-score pending. Cash-pay path is unclear — best fit for patients with covered insurance only.
Full Form Health review → · Visit Form Health →
Found — 74/100
Mixed model — branded GLP-1s plus compounded options. Its May 2026 score (v3.0 rubric) reflected limited public pharmacy disclosure; a v4.1 re-score is pending.
Full Found review → · Visit Found →
Mochi Health — 73/100
NP-led compounded semaglutide model. Scored 73/100 in our May 2026 review (v3.0 rubric); v4.1 re-score pending. Pricing is competitive in the compounded segment.
Full Mochi Health review → · Visit Mochi Health →
Noom Med — 70/100
Behavioral-program-led brand telehealth. Scored 70/100 in our May 2026 review (v3.0 rubric); v4.1 re-score pending. Strongest fit for users already in the Noom ecosystem.